Aligos Therapeutics 将在欧洲肝脏研究协会国际肝脏大会™ 2022 上

StephenW

Aligos Therapeutics 将在欧洲肝脏研究协会国际肝脏大会™ 2022 上展示 CAM 候选药物 ALG-000184 的 28 天安全性、疗效和药代动力学数据以及另外两个慢性乙型肝炎项目的非临床数据
美国东部时间 2022 年 5 月 3 日上午 8:02

Aligos 慢性乙型肝炎产品组合中三个慢性乙型肝炎项目的数据

加利福尼亚州南旧金山，2022 年 5 月 3 日 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) 是一家临床阶段的生物制药公司，专注于开发新的疗法，以解决病毒和肝脏疾病未满足的医疗需求。宣布该公司将在 6 月 22 日至 26 日举行的欧洲肝脏研究协会 2022 年国际肝脏大会 (EASL ILC 2022) 上展示三张海报，突出公司三个慢性乙型肝炎 (CHB) 项目的数据， 2022 年在英国伦敦的 ExCeL 伦敦展览中心。

这些海报预计将在 2022 年 6 月 25 日（星期六）上午 9 点（英国夏令时）展示海报的会议开始时提供给与会者。这些海报随后将在 Aligos 网站 www.aligos.com 的“演示文稿”部分的“科学演示文稿和出版物”页面上提供。

下面列出了迄今为止接受的每份摘要的详细介绍。

海报编号：782
海报标题：II 类衣壳组装调节剂 ALG-000184 在慢性乙型肝炎患者中的安全性、药代动力学和抗病毒活性
主讲人：袁文峰教授，MBBS，M.D.，Ph.D.，DSc，香港大学，香港
海报会议标题：病毒性乙型/丁型肝炎：治疗
海报会议的日期和时间：2022 年 6 月 25 日星期六上午 9 点 BST

海报编号：1410
海报标题：HBV siRNA，ALG-125755，在 AAV-HBV 小鼠疗效模型中展示了良好的非临床特征和显着且持久的乙型肝炎表面抗原减少
主持人：Megan Fitzgerald，博士
海报会议标题：病毒性乙型/丁型肝炎：治疗
海报会议的日期和时间：2022 年 6 月 25 日星期六上午 9 点 BST

海报编号：1627
海报标题：发现专门用于治疗慢性乙型肝炎的口服PDL1小分子抑制剂
主讲人：Francois Gonzalvez，博士
海报会议标题：病毒性乙型/丁型肝炎：治疗
海报会议的日期和时间：2022 年 6 月 25 日星期六上午 9 点 BST

“我们很高兴在我们的慢性乙型肝炎产品组合中展示与​​ Aligos 的三个项目相关的进展，”Aligos 董事长兼首席执行官 Lawrence Blatt 博士说。 “通过继续推进多样化的 CHB 产品组合，我们的目标是能够评估多种方法，为 CHB 患者提供更好的结果。”

会议将在大会开始前公布第二组已接受的摘要，其中可能包括 Aligos 提交的其他摘要

StephenW

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022
May 3, 2022 at 8:02 AM EDT

Data presented on three chronic hepatitis B programs in Aligos’ chronic hepatitis B portfolio

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will present three posters highlighting data from three of the company’s programs in chronic hepatitis B (CHB) at the European Association for the Study of the Liver’s International Liver Congress 2022 (EASL ILC 2022), taking place June 22 -26, 2022 at the ExCeL London Exhibition Centre in London, UK.

The posters are expected to be made available to conference attendees at the beginning of the sessions during which the posters will be presented, Saturday, June 25, 2022, 9 a.m. BST. The posters will be available subsequently on the “Scientific Presentation and Publications” page in the “Presentations” section of Aligos’ website at www.aligos.com.

Presentation details for each abstract accepted to date are listed below.

Poster number: 782
Poster title: Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B
Presenter: Professor Man-Fung Yuen, MBBS, M.D., Ph.D., DSc, University of Hong Kong, Hong Kong
Poster session title: Viral hepatitis B/D: therapy
Date and time of poster session: Saturday, June 25, 2022, 9 a.m. BST

Poster number: 1410
Poster title: The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model
Presenter: Megan Fitzgerald, Ph.D.
Poster session title: Viral hepatitis B/D: therapy
Date and time of poster session: Saturday, June 25, 2022, 9 a.m. BST

Poster number: 1627
Poster title: Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
Presenter: Francois Gonzalvez, Ph.D.
Poster session title: Viral hepatitis B/D: therapy
Date and time of poster session: Saturday, June 25, 2022, 9 a.m. BST

“We are pleased to present progress related to three of Aligos’ programs in our chronic hepatitis B portfolio,” said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos. “By continuing to advance a diverse CHB portfolio, we aim to be able to evaluate multiple approaches to providing better outcomes for patients with CHB.”

The conference will announce a second set of accepted abstracts before the beginning of the congress, which may include other abstracts submitted by Aligos